Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.43 |
| ▸ | GHSR | Q92847 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2297003 | 0.88 | GPR119 (0.53) | GPR119NAMPTMEN1ALDH1A1KMT2A | |
| SCHEMBL2792710 | 0.85 | ALDH1A1 (0.44) | MEN1ALDH1A1GAAKMT2A | |
| SCHEMBL2792293 | 0.79 | TEAD1 (0.47) | CSF1RKDRMEN1ALDH1A1GAA | |
| SCHEMBL4322579 | 0.78 | GPR119 (0.65) | GPR119MEN1ALDH1A1KMT2A | |
| SCHEMBL1277217 | 0.77 | ALDH1A1 (0.39) | MEN1ALDH1A1GAAKMT2A | |
| SCHEMBL31270200 | 0.75 | GPR119 (0.45) | GPR119NAMPT | |
| SCHEMBL1277324 | 0.75 | MEN1 (0.44) | GPR119NAMPTMEN1KMT2ACNR1 | |
| SCHEMBL1277226 | 0.74 | FAAH (0.66) | — | |
| SCHEMBL31270194 | 0.74 | GPR119 (0.44) | GPR119 | |
| SCHEMBL1277054 | 0.74 | FAAH (0.67) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8901111-B2 | Aryl-substituted heterocyclic urea modulators of fatty acid amide hydrolase | JANSSEN PHARMACEUTICA NV (BE) | 2014-12-02 | — | — | US | disclosed |
| US-20120088741-A1 | ARYL-SUBSTITUTED HETEROCYCLIC UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2012-04-12 | — | — | US | disclosed |
| WO-2010141809-A1 | ARYL-SUBSTITUTED HETEROCYCLIC UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088741-A1 | ARYL-SUBSTITUTED HETEROCYCLIC UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, APEH | CSF1R 1709/4885KDR 4743/4885GPR119 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.